Track Biocon Ltd live share price with 52 week high and low, interactive chart views, quick fundamentals, financial highlights, shareholding pattern, business segment highlights, peer comparison, dividends, bonus history and investor FAQs.
Switch between 1 Day, 5 Day, 1 Month and 1 Year chart views. Market feeds may be delayed.
These market-linked fields come from the latest available quote feed. Always verify price, market capitalization, 52 week range and valuation ratios on NSE, BSE or your broker before making decisions.
Biocon Ltd is a Bengaluru-headquartered global biopharmaceutical company focused on affordable access to complex medicines. Its portfolio includes biosimilars, generic formulations, APIs and research/manufacturing services. The company operates across therapy areas such as diabetes, oncology, immunology, ophthalmology, bone health, obesity and cardiovascular disease.
For beginners, Biocon is best understood as a science-led healthcare business where revenue depends on product approvals, regulated manufacturing, global tenders, pricing, patents, R&D execution and commercial partnerships. The business can show uneven profits because launches, licensing income, exceptional items, R&D investment and integration costs may vary from year to year.
For investors, key monitorables include biosimilar approvals and market share, generic peptide launches, US and Europe regulatory outcomes, EBITDA margin, debt reduction, interest cost, R&D pipeline, cash generation, shareholding pattern and corporate actions.
This page is educational and customer-focused. It does not provide a buy, sell or hold recommendation. Always verify the latest financial statements, dividend, bonus, split, shareholding and regulatory disclosures from Biocon investor relations, NSE and BSE filings.
Biocon earns money by developing, manufacturing and selling regulated healthcare products and by providing research, development and manufacturing services. Biosimilars can require heavy upfront investment but may offer long-term global opportunities after regulatory approvals. Generics and APIs can benefit from scale and complex chemistry but may face price pressure. CRDMO/research services depend on client demand, capacity utilization and scientific execution.
The company’s business model is not the same as a simple domestic formulations company. Investors should look at global product launches, partner economics, tender wins, manufacturing inspections, product concentration, debt and currency exposure alongside reported profit.
| Particulars | FY 2024 | FY 2025 | FY 2026 |
|---|---|---|---|
| Revenue from Operations | ₹14,756 Cr | ₹15,262 Cr | ₹16,927 Cr |
| Total Income | ₹15,621 Cr | ₹16,470 Cr | ₹17,270 Cr |
| R&D Expense | ₹1,154 Cr | ₹859 Cr | ₹982 Cr |
| EBITDA | ₹4,164 Cr | ₹4,374 Cr | ₹3,798 Cr |
| EBITDA Margin | 27% | 27% | 22% |
| Profit Before Tax Before Exceptional Items | ₹1,537 Cr | ₹1,790 Cr | ₹851 Cr |
| Net Profit Before Exceptional Items | ₹1,030 Cr | ₹981 Cr | ₹436 Cr |
| Reported Net Profit | ₹1,022 Cr | ₹1,013 Cr | ₹386 Cr |
Financial highlights are simplified for education. Check the latest audited annual report, quarterly results and exchange filings for complete schedules, accounting notes, exceptional items and restated figures.
| Particulars | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|
| Total Assets / Liabilities | ₹55,753 Cr | ₹58,540 Cr | ₹63,651 Cr |
| Fixed Assets | ₹30,644 Cr | ₹31,963 Cr | ₹38,860 Cr |
| Capital Work-in-Progress | ₹7,993 Cr | ₹8,508 Cr | ₹4,613 Cr |
| Investments | ₹1,000 Cr | ₹1,127 Cr | ₹1,779 Cr |
| Other Liabilities | ₹19,693 Cr | ₹18,534 Cr | ₹14,185 Cr |
| Balance Sheet Focus | Debt and integration costs | Cash generation and interest cost | Leverage reduction and asset efficiency |
Balance sheet analysis helps investors understand asset base, expansion, leverage, capital work-in-progress and liability structure. For Biocon, this is important because biosimilars and complex generics require manufacturing infrastructure, regulatory investment and R&D capability.
Balance sheet numbers should be verified from the latest audited consolidated financial statements and notes to accounts. Do not rely only on summarized figures when analyzing debt, cash, goodwill, intangible assets or related-party transactions.
| Business Segment | FY 2026 Revenue | Growth / Context | Investor Monitorable |
|---|---|---|---|
| Biosimilars | ₹10,431 Cr | Up 16% YoY on a like-to-like basis | Approvals, tenders, market share, pricing and manufacturing reliability |
| Generics: APIs and Formulations | ₹3,168 Cr | Up 17% YoY after adjustments | Complex generics, GLP-1/peptide launches, US pricing and regulatory outcomes |
| CRDMO / Research Services | ₹3,739 Cr | Up 3% YoY | Client concentration, biologics manufacturing demand and Syngene execution |
| Inter-segment Elimination | -₹411 Cr | Internal group transactions removed | Focus on consolidated operating revenue and segment margin |
Segment mix matters because each business has a different risk profile. Biosimilars depend on regulated market access and manufacturing reliability, generics can face price erosion, and CRDMO/research services depend on client pipelines and capacity utilization.
| Metric | Latest / Context | How beginners can read it |
|---|---|---|
| Stock P/E | Live feed unavailable | P/E may look high when earnings are affected by exceptional items or integration costs |
| Price to Book | Live feed unavailable | Compare with pharma peers and Biocon’s own historical band |
| Dividend Yield | Live feed unavailable | Yield can change with price and board-approved dividend |
| ROE / ROCE | Low single digit in recent market-data snapshots | Track improvement as debt, margins and integration costs normalize |
| R&D Intensity | ₹982 Cr in FY26 | High R&D can reduce short-term profit but supports product pipeline |
| EBITDA Margin | 22% in FY26 | Monitor biosimilar mix, generics pricing, interest cost and operating leverage |
| Company | Symbol | Price | Market Cap | P/E | P/B | Dividend Yield |
|---|---|---|---|---|---|---|
| Biocon Ltd | BIOCON.NS | — | — | — | — | — |
| Sun Pharma | SUNPHARMA.NS | — | — | — | — | — |
| Cipla | CIPLA.NS | — | — | — | — | — |
| Dr. Reddy’s Labs | DRREDDY.NS | — | — | — | — | — |
| Lupin | LUPIN.NS | — | — | — | — | — |
| Syngene International | SYNGENE.NS | — | — | — | — | — |
Peer comparison is only a starting point. Biocon has a different mix of biosimilars, generics and CRDMO exposure compared with many pharma peers. Verify live peer data and compare business quality, balance sheet, pipeline, margins and regulatory risk before drawing conclusions.
| Year | Dividend Detail | Note |
|---|---|---|
| FY 2025-26 | Final dividend recommended at ₹0.50 per share | Verify approval, record date, ex-date and payment details from official exchange filings |
| FY 2024-25 | Dividend of ₹0.50 per share was recommended/declared in market disclosures | Check company dividend page and NSE/BSE announcements for entitlement details |
| General Policy | Biocon has a history of paying dividends, but payment is not guaranteed | Dividend depends on profits, cash flow, board approval and shareholder approval where applicable |
| Action | Detail | Note |
|---|---|---|
| Bonus Issue | 1:1 bonus with ex-date in June 2019 | Historical corporate action; verify adjusted data before long-term return calculations |
| Bonus Issue | 2:1 bonus with ex-date in June 2017 | Historical corporate action; verify official records before using in analysis |
| Bonus Issue | 1:1 bonus with ex-date in September 2008 | Older corporate action; check exchange records for exact dates and ratios |
| Face Value | ₹5.00 per share in recent market-data snapshots | Face value can change through splits or consolidations; verify latest filings |
Always verify the latest dividend, bonus, split, record date, ex-date and entitlement from official exchange filings. Historical corporate actions affect adjusted charts and long-term returns.
These FAQs help users understand Biocon beyond the share price, including its products, business model, risks, dividends, corporate actions, customer relevance and investment monitorables.
Biocon Ltd is an Indian global biopharmaceutical company headquartered in Bengaluru. It develops, manufactures and commercializes biosimilars, generic formulations, complex APIs and related research/manufacturing services through group businesses such as Biocon Biologics and Syngene. Retail investors should verify the latest company structure and segment data from official annual reports and exchange filings.
The NSE trading symbol is BIOCON and the Yahoo Finance-compatible NSE symbol used for live quote and chart data is BIOCON.NS. The BSE scrip code is 532523. Market data can be delayed or temporarily unavailable, so investors should cross-check live prices on NSE, BSE or their broker platform.
Biocon is mainly tracked through biosimilars, generics including APIs and generic formulations, and CRDMO/research services through Syngene. The company also discusses novel biologics and pipeline assets. Segment contribution may change after portfolio sales, acquisitions, integrations or regulatory approvals.
Biosimilars are highly similar versions of approved biologic medicines. They can improve access to complex therapies in areas such as diabetes, oncology, immunology, ophthalmology and bone health. For Biocon, biosimilars are important because they require scientific capability, regulatory approvals, global manufacturing scale and commercial access.
Biocon earns revenue by selling biosimilars, generic formulations and APIs, and through research, development and manufacturing services. It may also earn licensing income, milestone income or other income in some periods. Investors should separate recurring operating performance from exceptional gains or one-time events.
Beginners can track revenue growth, biosimilar market share, US and Europe approvals, EBITDA margin, R&D spending, debt, interest cost, cash flow, regulatory observations, product launches, pricing pressure, patent expiries, shareholding changes and corporate actions. This page is educational and does not provide buy or sell advice.
Biocon has declared dividends in the past, but dividends are not guaranteed. Dividend amount, record date, ex-date and eligibility should always be verified from company announcements, annual reports and NSE/BSE corporate action filings.
Biocon has announced bonus issues in past years, including historical bonus actions such as 1:1 and 2:1 issues. Before relying on any corporate action history, investors should verify ex-date, record date, ratio and adjusted price history through NSE, BSE and official company disclosures.
Key risks include regulatory delays, USFDA or other inspection outcomes, biosimilar pricing pressure, product launch timing, patent litigation, high R&D cost, debt and interest cost, currency movements, integration execution, supply reliability and competition from global pharmaceutical companies.
Customers and patients should understand Biocon as a regulated medicines company focused on affordable access to complex therapies. Product use, dosage, suitability and side effects should always be discussed with a qualified doctor or pharmacist. This stock page is for financial education, not medical advice.
Biocon is different from many pharma peers because it has a large biosimilars focus along with generics and CRDMO exposure. Investors often compare it with large pharmaceutical and healthcare companies on valuation, profitability, R&D pipeline, regulatory track record, margins, return ratios and balance sheet strength.
The latest financials, dividends, bonus/split actions, shareholding pattern and board updates should be checked from Biocon investor relations, NSE announcements, BSE filings, quarterly results, annual reports and official corporate action notices.
No. Live price is only one input. Investors should also review the latest financial statements, valuation, debt, R&D pipeline, regulatory disclosures, management commentary, business risks and personal risk profile. This page avoids buy or sell recommendations.
A P/E ratio can look high when earnings are temporarily low due to integration costs, interest cost, exceptional items, high R&D expense or product-cycle timing. Investors should compare reported profit, profit before exceptional items and operating cash generation before drawing conclusions.
